These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 16428034)

  • 1. Epidemiology and molecular biology of Barrett esophagus.
    Casson AG; Williams L; Guernsey DL
    Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.
    Williams LJ; Guernsey DL; Casson AG
    Curr Oncol; 2006 Feb; 13(1):33-43. PubMed ID: 17576439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular biology of esophageal adenocarcinoma.
    Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
    J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I; Tannapfel A
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.
    Casson AG; Zheng Z; Evans SC; Geldenhuys L; van Zanten SV; Veugelers PJ; Porter GA; Guernsey DL
    Cancer; 2005 Aug; 104(4):730-9. PubMed ID: 15971196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Barrett's esophagus with dysplasia.
    Hagen JA
    Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):285-9. PubMed ID: 9263347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
    Abraham SC; Wang H; Wang KK; Wu TT
    Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history.
    Goldblum JR; Lauwers GY
    Semin Diagn Pathol; 2002 Feb; 19(1):12-9. PubMed ID: 11936261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma.
    Chang JT; Katzka DA
    Arch Intern Med; 2004 Jul; 164(14):1482-8. PubMed ID: 15277277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and recognition of early esophageal neoplasia.
    Herszényi L; Pregun I; Tulassay Z
    Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical and histopathologic focus on Barrett esophagus and Barrett-related dysplasia.
    Voltaggio L; Montgomery EA; Lam-Himlin D
    Arch Pathol Lab Med; 2011 Oct; 135(10):1249-60. PubMed ID: 21970480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Barrett esophagus and Barrett carcinoma].
    Kruyt PH; van Sandick JW; van Lanschot JJ; Offerhaus GJ; Tytgat GN; Obertop H
    Ned Tijdschr Geneeskd; 1997 May; 141(18):869-73. PubMed ID: 9273450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for esophageal cancer development.
    Falk GW
    Surg Oncol Clin N Am; 2009 Jul; 18(3):469-85. PubMed ID: 19500737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastroesophageal reflux disease and malignancy].
    Richert Z; Robaszkiewicz M
    Rev Prat; 2008 Sep; 58(13):1414-5, 1417, 1419-20. PubMed ID: 18924321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
    Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.